Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOLOTHROK: DOACs vs LMWH for Thromboprophylaxis After Total Knee Arthroplasty
NCT07869615Recruiting
- Sponsor
- Military Hospital of Tunis
- Start
- Sep 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Randomised, single-blind trial of apixaban and rivaroxaban in venous thromboembolism (VTE) (3 arms), sponsored by Military Hospital of Tunis. Primary endpoint: Mean Peak Systolic Velocity of the Common Femoral Vein at Day 28. Started Sep 2026; status: recruiting.
02
Drugs
apixabanrivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07869615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07869615.